Home | Sitemap | Contact Us     Search Ranbaxy for  
  Quick Links
 
 
   
   
 
    
 
     
 
   
 
 


Home
Investor Relations > Financials > P & L Account > Ranbaxy Laboratories Limited - Consolidated (Indian GAAP)
 

     P & L Account


Untitled Document

 
CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED DECEMBER 31, 2006
 
Rs. in Million
 
Schedule
2006
2005
INCOME
Operating income
15
61,915.78
53,676.83
  Less excise duty  
481.72
860.96
   
61,434.06
52,815.87
Other income
16
564.35
616.28
 
61,998.41
53,432.15
EXPENDITURE
Materials
17
23,733.09
22,212.71
Manufacturing
18
3,098.76
2,549.40
Personnel
19
7,955.29
6,785.66
Selling, general and administration
20
13,866.94
13,231.94
Research and development
21
3,954.79
4,925.07
 
52,608.87
49,704.78
PROFIT BEFORE INTEREST, DEPRECIATION,
AMORTIZATION AND IMPAIRMENT
9,389.54
3,727.37
Interest
1,036.32
671.16
Depreciation, amortization and impairment
22
1,842.88
1,444.52
PROFIT FROM OPERATIONS
Continuing operations
6,510.34
1,371.22
Discontinued operations
240.47
PROFIT FROM OPERATIONS BEFORE EXCEPTIONAL ITEMS
6,510.34
1,611.69
Interest in Joint venture written off
(121.80)
Profit from sale of undertaking and a subsidiary
454.95
PROFIT BEFORE TAX
6,510.34
1,944.84
Provision for tax
23
1,356.74
(697.57)
PROFIT AFTER TAX
5,153.60
2,642.41
Minority interests
50.21
25.35
PROFIT AFTER TAX AND MINORITY INTERESTS
5,103.39
2,617.06
Tax - earlier years
148.06
(61.78)
Balance as per last balance sheet
1,253.94
2,532.50
Transfer from Foreign projects reserve
22.95
30.65
BALANCE AVAILABLE FOR APPROPRIATION
6,528.34
5,118.43
APPROPRIATIONS
Dividend
  Interim
3,168.94
931.11
  Final (proposed)
2,235.55
Tax on dividend
444.44
447.83
Transfer to General reserve
450.00
250.00
Surplus carried forward
2,464.96
1,253.94
 
6,528.34
5,118.43
EARNINGS PER SHARE (Rs.)
24
Including discontinued operations and exceptional items
  Basic
14.09
6.87
  Diluted
13.17
6.84
Excluding discontinued operations and exceptional items
  Basic
14.09
5.70
  Diluted
13.17
5.69
SIGNIFICANT ACCOUNTING POLICIES
25
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
26
The schedules referred to above form an integral part of the consolidated financial statements.

This is the consolidated profit and loss account referred to in our report of even date.


  On behalf of the Board of Directors
For WALKER, CHANDIOK & CO
Chartered Accountants

TEJENDRA KHANNA
Chairman
 

VINOD CHANDIOK
Partner
Membership No. 10093

 


DR. BRIAN W. TEMPEST
Chief Mentor &
Executive Vice Chairman

MALVINDER MOHAN SINGH
CEO & Managing Director

 

ATUL SOBTI
Chief Operating Officer &
Whole-time Director

  RAM S. RAMASUNDAR
President & CFO

Place : Gurgaon
Dated : March 29, 2007


SUSHIL K. PATAWARI

Secretary